HIV infection and AIDS: Antiretroviral therapy

Abstract

The therapeutic management of human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) is constantly evolving and improving. Newer drugs with greater efficacy and fewer side effects continue to broaden therapeutic options, offering better pharmacokinetic profiles, higher genetic barriers, and easier dosing regimens. Some companies have already begun marketing co-formulated drugs, offering single-tablet, once-a-day treatments, and more are sure to follow. Successful treatments have led to significantly prolonged survival rates. Such successes, however, have brought complications: when patients survive longer, comorbidities begin to emerge, inducing premature ageing and frailty. Treating HIV/AIDS becomes more complicated as a result, requiring the cooperation of many specialists.